Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.

[1]  R. Passman,et al.  Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. , 2014, The American journal of cardiology.

[2]  W. Aronow,et al.  Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. , 2014, The American journal of cardiology.

[3]  A. Camm,et al.  Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  S. Härtter,et al.  Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. , 2013, British journal of clinical pharmacology.

[5]  M. Feuring,et al.  Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran , 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  S. Yusuf,et al.  Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[7]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[8]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[9]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[10]  E. Davie,et al.  An Overview of the Structure and Function of Thrombin , 2006, Seminars in thrombosis and hemostasis.

[11]  D. Dwyre,et al.  The effect of dabigatran on select specialty coagulation assays. , 2013, American journal of clinical pathology.

[12]  J. Stangier.  Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate , 2008, Clinical pharmacokinetics.